may 3, 2016 - FDA convened a joint meeting of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee to discuss results from assessments of the extended-release and long- acting (ER/LA) Opioid Analgesics Risk Evaluation and Mitigation Strategies (REMS)
Added to timeline:
Date:
may 3, 2016
Now
~ 10 years ago